Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.68 |
| ▸ | L3MBTL3 | Q96JM7 | 4/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.54 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2881259 | 0.99 | HRH3 (0.67) | HRH3L3MBTL3L3MBTL1HTR2BMBTD1 | |
| SCHEMBL2884880 | 0.89 | HRH3 (0.69) | HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL2884371 | 0.89 | HRH3 (0.71) | HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL2878753 | 0.89 | HRH3 (0.71) | HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL2886056 | 0.88 | HRH3 (0.67) | HRH3L3MBTL3L3MBTL1 | |
| Hydrochloric Acid SCHEMBL2885717 | 0.88 | HRH3 (0.70) | HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL2884311 | 0.88 | HRH3 (0.65) | HRH3L3MBTL3L3MBTL1MBTD1MEN1 | |
| SCHEMBL2884415 | 0.87 | HRH3 (0.67) | HRH3L3MBTL3L3MBTL1MEN1ALDH1A1 | |
| SCHEMBL2886669 | 0.87 | HRH3 (0.67) | HRH3L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL2884872 | 0.87 | HRH3 (0.69) | HRH3L3MBTL3L3MBTL1MBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820825-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2010-10-26 | — | — | US | claimed |
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH (US) | 2007-09-20 | — | — | US | claimed |
| US-7820825-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2010-10-26 | — | — | US | disclosed |
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | HNMT, HRH4, HRH3 | HRH3 3/4885L3MBTL3 3550/4885L3MBTL1 4513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.